To evaluate competitors and conduct impact analysis in chronic Graft versus Host Disease (cGvHD) space for a Phase-3 stem cell asset.
Approach
Conducted a deep dive into the cGvHD space, its treatment algorithm and various stem cell therapies in this area
Assessed inline and pipeline candidates for cGvHD Treatment and categorized them based on their MOA, stage of development, target patient pool, line of therapy and ROA
Analyzed the impact of each asset based on probability of regulatory and clinical success
Conducted detailed SWOT analysis of all key assets in the landscape
Outcome
Summarized the unmet medical needs while managing cGvHD
Identified potential threats for the client’s Phase 3 asset based on comprehensive competitor profiles which included details on MOA, clinical profile and potential commercial profile
Mapped order of entry of the key stem cell therapies
Client Benefits
Our analysis provided an overview of cGvHD landscape outlining the key stem cell therapies
Helped identify key differentiators against the competition
Based on the findings, the client was able to assess market dynamics and build revenue projections
Our analysis and report were instrumental in the client’s strategic decision making with regards to the cGvHD market
